goldennet

Genomics’ Earnings Per Share (EPS) in the previous year was NT$1.15, plans to increase capital expenditure and aims to distribute dividends of NT$0.3

"Genomics BioSci & Tech. Co. Ltd., Taiwan’s leading genetic sequencing company (hereafter referred to as “Genomics”, stock code: 4195), announced today (15th) the Board of Directors have passed the financial report of 2022 and the proposal on profit distribution.

Benefiting from the increased demands of testing services and equipment procurement from the scientific research organizations and the contributions from the sales of the newly added agency of COVID-19 rapid screening products, the combined revenue of Genomics for the previous year was NT$419 million, an annual growth of 7.45%. In terms of profits, due to the investment in the construction of GMP plant and expenditures on expansion of R&D teams, the core business has experienced losses, but with upgraded laboratory equipment and process optimization, the gross margin has increased from 28% in 2021 to 32% in 2022. In addition, the profit from the disposal of reinvested stocks pushed up the net profit attributable to the parent company's owners to NT$71.59 million, which is a significant increase of 282% from the previous year, and the after-tax earnings per share (EPS) was NT$1.15."